Literature DB >> 24551304

Re-examination of sinusoidal deposition of complement 4d in liver allografts: experience from a single institution.

Mohannad Dugum1, Medhat Askar2, Rish K Pai3, Lisa Yerian3, Ana Bennett3, James McMahon3, Hao Xie4, Bijan Eghtesad5, Ibrahim Hanouneh6, Xiuli Liu3.   

Abstract

Complement 4d (C4d) is a marker of complement activation that has been used to evaluate humoral rejection in renal and heart allografts. Studies suggested a role for C4d detection in liver allografts in diagnosing acute cellular and humoral rejection but none correlated this with the pre-transplant liver disease. Our study analyzed the association of C4d deposition in liver allografts with the pre-transplant liver disease. C4d deposition was evaluated by indirect immunofluorescence and correlated with lymphocytotoxic crossmatch results, post-transplant clinicopathological diagnosis and type of pre-transplant liver disease. Allograft biopsies were classified by the native liver disease. After excluding 20 patients with rare liver diseases; C4d deposition was evaluated in 506 biopsies from 310 patients including 25 with PSC, 198 with viral hepatitis and 87 with other diseases. C4d immunereactivity distribution was not different among biopsies from patients with different lymphocytotoxic crossmatch results. Sinusoidal C4d deposition was noted in 11.9% of biopsies and 15.2% of patients (in one or more biopsies). 26% (9/35) of biopsies from patients with PSC had sinusoidal C4d deposition; more frequently than from patients with viral hepatitis 12% (43/348) (p=0.04) and other liver diseases 7% (8/123) (p=0.005). In conclusion, C4d deposition in liver allografts is independent of the crossmatch results. It occurs with a variety of pathologic abnormalities and underlying liver diseases; but is more frequent in patients with PSC. This suggests that mechanisms other than allo-immunity activate complement. The mechanisms and clinical significance of C4d deposition in liver allografts in patients with PSC remain to be determined.

Entities:  

Keywords:  Liver allograft; complement; lymphocytotoxic antibody; primary sclerosing cholangitis; rejection

Mesh:

Substances:

Year:  2014        PMID: 24551304      PMCID: PMC3925928     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  20 in total

Review 1.  Antibody-mediated organ-allograft rejection.

Authors:  Robert B Colvin; R Neal Smith
Journal:  Nat Rev Immunol       Date:  2005-10       Impact factor: 53.106

2.  Vascular deposition of complement C4d is increased in liver allografts with chronic rejection.

Authors:  Timi Martelius; Leena Halme; Johanna Arola; Krister Höckerstedt; Irmeli Lautenschlager
Journal:  Transpl Immunol       Date:  2009-06-21       Impact factor: 1.708

Review 3.  Banff schema for grading liver allograft rejection: an international consensus document.

Authors: 
Journal:  Hepatology       Date:  1997-03       Impact factor: 17.425

Review 4.  Treatment options for primary sclerosing cholangitis.

Authors:  Emmanouil Sinakos; Keith Lindor
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2010-08       Impact factor: 3.869

5.  The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation.

Authors:  A I Musat; R M Agni; P Y Wai; J D Pirsch; D F Lorentzen; A Powell; G E Leverson; J M Bellingham; L A Fernandez; D P Foley; J D Mezrich; A M D'Alessandro; M R Lucey
Journal:  Am J Transplant       Date:  2011-03       Impact factor: 8.086

6.  Humoral immune system and ulcerative colitis activity. II. Complement level.

Authors:  A Hermanowicz; Z Sliwiński; Z Nawarska; B Banaś
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  1984       Impact factor: 4.291

7.  Sinusoidal C4d deposits in liver allografts indicate an antibody-mediated response: diagnostic considerations in the evaluation of liver allografts.

Authors:  Tomasz Kozlowski; Kenneth Andreoni; John Schmitz; Paul Hideo Hayashi; Volker Nickeleit
Journal:  Liver Transpl       Date:  2012-06       Impact factor: 5.799

8.  Activation of the complement system in primary sclerosing cholangitis.

Authors:  G Senaldi; P T Donaldson; S Magrin; J M Farrant; G J Alexander; D Vergani; R Williams
Journal:  Gastroenterology       Date:  1989-12       Impact factor: 22.682

9.  Pathologic findings in lung allografts with anti-HLA antibodies.

Authors:  Matthew M DeNicola; Sam S Weigt; John A Belperio; Elaine F Reed; David J Ross; W Dean Wallace
Journal:  J Heart Lung Transplant       Date:  2013-01-10       Impact factor: 10.247

10.  High frequency of autoantibodies in patients with primary sclerosing cholangitis that bind biliary epithelial cells and induce expression of CD44 and production of interleukin 6.

Authors:  B Xu; U Broome; B-G Ericzon; S Sumitran-Holgersson
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

View more
  1 in total

1.  Human interleukin-10 gene inhibits acute rejection by triggering apoptosis in allograft vascular transplantation.

Authors:  Haibo Liu; Shunzhang Yang; Xuejun Sun; Tianbao Chen
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.